4) Burger RA, Brady MF, Bookman MA, et al. Incor- poration of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011 ; 365 : 2473.
5) Kosty MP, Brahmer JR, Jahanzeb M, et al. Use of bevacizumab (RV) after induction therapy is asso-11 :32ciated with survival benefit in patients (pts) with non-small cell ling cancer (NSCLC) in the ARIES observational cohort study (OCS) [abstract 9020]. European Journal of Cancer 2011 ; 47 Suppl 1 : S598.